These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

259 related articles for article (PubMed ID: 27498212)

  • 1. A decade of adaptation: Regulatory contributions of the World Health Organization to the Global Action Plan for Influenza Vaccines (2006-2016).
    Palkonyay L; Fatima H
    Vaccine; 2016 Oct; 34(45):5414-5419. PubMed ID: 27498212
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Global production of seasonal and pandemic (H1N1) influenza vaccines in 2009-2010 and comparison with previous estimates and global action plan targets.
    Partridge J; Kieny MP;
    Vaccine; 2010 Jul; 28(30):4709-12. PubMed ID: 20488262
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Influenza vaccine: globalization of public health stakes].
    Collin N; Briand S
    Med Trop (Mars); 2009 Aug; 69(4):322. PubMed ID: 19725377
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Stakeholders' perceptions of 10years of the Global Action Plan for Influenza Vaccines (GAP) - Results from a survey.
    Nannei C; Goldin S; Torelli G; Fatima H; Kumar K; Bubb-Humfryes O; Stenson B; Sparrow E
    Vaccine; 2016 Oct; 34(45):5393-5399. PubMed ID: 27646029
    [TBL] [Abstract][Full Text] [Related]  

  • 5. WHO initiative to increase global and equitable access to influenza vaccine in the event of a pandemic: supporting developing country production capacity through technology transfer.
    Friede M; Palkonyay L; Alfonso C; Pervikov Y; Torelli G; Wood D; Kieny MP
    Vaccine; 2011 Jul; 29 Suppl 1():A2-7. PubMed ID: 21684422
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Development and approval of live attenuated influenza vaccines based on Russian master donor viruses: Process challenges and success stories.
    Rudenko L; Yeolekar L; Kiseleva I; Isakova-Sivak I
    Vaccine; 2016 Oct; 34(45):5436-5441. PubMed ID: 27593158
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Live attenuated pandemic influenza vaccine: clinical studies on A/17/California/2009/38 (H1N1) and licensing of the Russian-developed technology to WHO for pandemic influenza preparedness in developing countries.
    Rudenko L; van den Bosch H; Kiseleva I; Mironov A; Naikhin A; Larionova N; Bushmenkov D
    Vaccine; 2011 Jul; 29 Suppl 1():A40-4. PubMed ID: 21684428
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A global pandemic influenza vaccine action plan.
    Kieny MP; Costa A; Hombach J; Carrasco P; Pervikov Y; Salisbury D; Greco M; Gust I; LaForce M; Franco-Paredes C; Santos JI; D'Hondt E; Rimmelzwaan G; Karron R; Fukuda K
    Vaccine; 2006 Sep; 24(40-41):6367-70. PubMed ID: 17240560
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Does having a seasonal influenza program facilitate pandemic preparedness? An analysis of vaccine deployment during the 2009 pandemic.
    Porter RM; Goldin S; Lafond KE; Hedman L; Ungkuldee M; Kurzum J; Azziz-Baumgartner E; Nannei C; Bresee JS; Moen A
    Vaccine; 2020 Jan; 38(5):1152-1159. PubMed ID: 31839465
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Vaccine production capacity for seasonal and pandemic (H1N1) 2009 influenza.
    Collin N; de Radiguès X;
    Vaccine; 2009 Aug; 27(38):5184-6. PubMed ID: 19563891
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Lessons from pandemic influenza A(H1N1): the research-based vaccine industry's perspective.
    Abelin A; Colegate T; Gardner S; Hehme N; Palache A
    Vaccine; 2011 Feb; 29(6):1135-8. PubMed ID: 21115061
    [TBL] [Abstract][Full Text] [Related]  

  • 12. PIPDeploy: Development and implementation of a gamified table top simulation exercise to strengthen national pandemic vaccine preparedness and readiness.
    Ghiga I; Richardson S; Álvarez AMR; Kato M; Naidoo D; Otsu S; Nguyen PT; Nguyen PN; Nguyen T
    Vaccine; 2021 Jan; 39(2):364-371. PubMed ID: 33293160
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The 2015 global production capacity of seasonal and pandemic influenza vaccine.
    McLean KA; Goldin S; Nannei C; Sparrow E; Torelli G
    Vaccine; 2016 Oct; 34(45):5410-5413. PubMed ID: 27531411
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Technology transfer of oil-in-water emulsion adjuvant manufacturing for pandemic influenza vaccine production in Romania: Preclinical evaluation of split virion inactivated H5N1 vaccine with adjuvant.
    Stavaru C; Onu A; Lupulescu E; Tucureanu C; Rasid O; Vlase E; Coman C; Caras I; Ghiorghisor A; Berbecila L; Tofan V; Bowen RA; Marlenee N; Hartwig A; Bielefeldt-Ohmann H; Baldwin SL; Van Hoeven N; Vedvick TS; Huynh C; O'Hara MK; Noah DL; Fox CB
    Hum Vaccin Immunother; 2016 Apr; 12(4):1009-26. PubMed ID: 26618392
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Improving influenza vaccine virus selection: report of a WHO informal consultation held at WHO headquarters, Geneva, Switzerland, 14-16 June 2010.
    ; Ampofo WK; Baylor N; Cobey S; Cox NJ; Daves S; Edwards S; Ferguson N; Grohmann G; Hay A; Katz J; Kullabutr K; Lambert L; Levandowski R; Mishra AC; Monto A; Siqueira M; Tashiro M; Waddell AL; Wairagkar N; Wood J; Zambon M; Zhang W
    Influenza Other Respir Viruses; 2012 Mar; 6(2):142-52, e1-5. PubMed ID: 21819547
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Chemistry, manufacturing and control (CMC) and clinical trial technical support for influenza vaccine manufacturers.
    Wahid R; Holt R; Hjorth R; Berlanda Scorza F
    Vaccine; 2016 Oct; 34(45):5430-5435. PubMed ID: 27484011
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Challenges and successes for the grantees and the Technical Advisory Group of WHO's influenza vaccine technology transfer initiative.
    Grohmann G; Francis DP; Sokhey J; Robertson J
    Vaccine; 2016 Oct; 34(45):5420-5424. PubMed ID: 27506497
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pandemic influenza vaccines: meeting the supply, distribution and deployment challenges.
    Hessel L;
    Influenza Other Respir Viruses; 2009 Jul; 3(4):165-70. PubMed ID: 19627373
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Strengthening the influenza vaccine virus selection and development process: Report of the 3rd WHO Informal Consultation for Improving Influenza Vaccine Virus Selection held at WHO headquarters, Geneva, Switzerland, 1-3 April 2014.
    Ampofo WK; Azziz-Baumgartner E; Bashir U; Cox NJ; Fasce R; Giovanni M; Grohmann G; Huang S; Katz J; Mironenko A; Mokhtari-Azad T; Sasono PM; Rahman M; Sawanpanyalert P; Siqueira M; Waddell AL; Waiboci L; Wood J; Zhang W; Ziegler T;
    Vaccine; 2015 Aug; 33(36):4368-82. PubMed ID: 26148877
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Unlicensed pandemic influenza A H1N1 vaccines.
    Caplan AL
    Lancet; 2010 Feb; 375(9713):444-5. PubMed ID: 19914708
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 13.